AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23019944 — intervention group
Group type: EXPERIMENTAL
Intervention: Maixuekang Capsule (MC)
Number of subjects: 236
Study 20573448 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block with perineural ropivacaine 0.2% for 4 days
Number of subjects: 77
Study 18055726 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1,000 mg) and Vitamin E (400 International Units)
Number of subjects: 734
Study 18055726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 734
Study 18055726 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C and Vitamin E
Number of subjects: 734
Study 16126331 — intervention group
Group type: EXPERIMENTAL
Intervention: SpeediCath
Number of subjects: 49
Study 16126331 — intervention group
Group type: EXPERIMENTAL
Intervention: LoFric
Number of subjects: 49
Study 16126331 — intervention group
Group type: COMPARATOR
Intervention: InCare Advance Plus (gel-lubricated uncoated catheter)
Number of subjects: 49
Study 16126331 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic catheters (SpeediCath and LoFric)
Number of subjects: 49
Study 11857663 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral incision of the prostate (TUIP)
Number of subjects: 100
Study 11857663 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 100
Study 8000836 — intervention group
Group type: EXPERIMENTAL
Intervention: Iotrolan (iso-osmolar non-ionic contrast medium)
Number of subjects: 0
Study 8000836 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol (conventional non-ionic contrast medium) with adrenaline
Number of subjects: 0
Study 8000836 — intervention group
Group type: COMPARATOR
Intervention: Iohexol (conventional non-ionic contrast medium) without adrenaline
Number of subjects: 0
Study 2905150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg
Number of subjects: 0
Study 2905150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 50 mg
Number of subjects: 0
Study 29946832 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw-retained monolithic zirconia crowns
Number of subjects: 22
Study 29946832 — intervention group
Group type: COMPARATOR
Intervention: Cemented porcelain-fused-to-metal crowns
Number of subjects: 22
Study 28925703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic tetramer of zirconium hydroxide [Zr4(OH)16]
Number of subjects: 0
Study 25872563 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained inflation (SI) with PEEP (initial SI at 20 cm H2O for 15 seconds followed by a second SI at 25 cm H2O for 15 seconds)
Number of subjects: 600
Study 25872563 — intervention group
Group type: COMPARATOR
Intervention: Intermittent positive pressure ventilation (IPPV) with PEEP
Number of subjects: 600
Study 23758662 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralised laboratory positioning of Xpert MTB/RIF system
Number of subjects: 0
Study 23758662 — intervention group
Group type: COMPARATOR
Intervention: Primary health care clinic positioning of Xpert MTB/RIF system
Number of subjects: 0
Study 21647578 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 26576 (0.1-10 mg/kg, i.v.)
Number of subjects: 41
Study 21647578 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 26576 (100 mg QD)
Number of subjects: 41
Study 21647578 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 26576 (400 mg BID)
Number of subjects: 41
Study 21647578 — intervention group
Group type: EXPERIMENTAL
Intervention: EC(80) target concentration
Number of subjects: 41
Study 19318455 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen (TD E2)
Number of subjects: 12
Study 19318455 — intervention group
Group type: COMPARATOR
Intervention: Conjugated oral estrogen
Number of subjects: 12
Study 16892908 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero-inflated Negative Binomial (ZINB) model
Number of subjects: 0
Study 16892908 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Binomial Hurdle (NBH) model
Number of subjects: 0
Study 16892908 — intervention group
Group type: COMPARATOR
Intervention: Poisson model
Number of subjects: 0
Study 16892908 — intervention group
Group type: COMPARATOR
Intervention: Negative Binomial (NB) model
Number of subjects: 0
Study 16892908 — intervention group
Group type: COMPARATOR
Intervention: Zero-inflated Poisson (ZIP) model
Number of subjects: 0
Study 16892908 — intervention group
Group type: COMPARATOR
Intervention: Poisson Hurdle (PH) model
Number of subjects: 0
Study 15605118 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (monotherapy or combined with mood stabilizers)
Number of subjects: 0
Study 15605118 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 0
Study 11599198 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (average starting dosage 55 mg)
Number of subjects: 243
Study 11599198 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone with ACE-inhibitor
Number of subjects: 243
Study 11599198 — intervention group
Group type: COMPARATOR
Intervention: ACE-inhibitor
Number of subjects: 243
Study 11599198 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 243
Study 11599198 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone and ACE-inhibitor
Number of subjects: 243
Study 9394235 — intervention group
Group type: EXPERIMENTAL
Intervention: Faropenem (FRPM) only (S-group)
Number of subjects: 40
Study 9394235 — intervention group
Group type: COMPARATOR
Intervention: Faropenem (FRPM) in combination with Enteronon-R (E-group)
Number of subjects: 40
Study 9394235 — intervention group
Group type: EXPERIMENTAL
Intervention: Faropenem (FRPM)
Number of subjects: 40
Study 8424507 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (EM) 100 micrograms/kg
Number of subjects: 0
Study 8424507 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (EM)
Number of subjects: 0
Study 8424507 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine (IM)
Number of subjects: 0
Study 3263098 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 0
Study 3263098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 5072238 — intervention group
Group type: EXPERIMENTAL
Intervention: +/- propranolol (120 mg)
Number of subjects: 0
Study 5072238 — intervention group
Group type: EXPERIMENTAL
Intervention: +/- sotalol (240 mg)
Number of subjects: 0
Study 5072238 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sotalol and propranolol
Number of subjects: 0
Study 31100124 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture (Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium bifidum, and Bifidobacterium lactis)
Number of subjects: 181
Study 31100124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 31100124 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture
Number of subjects: 181
Study 31712617 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 3 months
Number of subjects: 43
Study 31712617 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (table soccer) for 3 months
Number of subjects: 43
Study 28111006 — intervention group
Group type: EXPERIMENTAL
Intervention: Early motion protocol (starting 2 to 3 days after surgery)
Number of subjects: 73
Study 28111006 — intervention group
Group type: COMPARATOR
Intervention: Delayed motion protocol (starting 28 days after surgery)
Number of subjects: 73
Study 25907815 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid naltrexone induction with buprenorphine-clonidine procedure
Number of subjects: 150
Study 22956408 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-D immunoglobulin (50 μg/kg)
Number of subjects: 60
Study 22956408 — intervention group
Group type: EXPERIMENTAL
Intervention: methylprednisolone (2 mg/kg/day)
Number of subjects: 60
Study 22956408 — intervention group
Group type: EXPERIMENTAL
Intervention: intravenous immunoglobulin (IVIG, 0.4 g/kg/day for 5 days)
Number of subjects: 60
Study 22956408 — intervention group
Group type: COMPARATOR
Intervention: IVIG
Number of subjects: 60
Study 22003869 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (AS)
Number of subjects: 24
Study 22003869 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 24
Study 22003869 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2A6 genotyping
Number of subjects: 24
Study 22003869 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (female)
Number of subjects: 24
Study 18704101 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TMS (transcranial magnetic stimulation) administered to the left dorsolateral prefrontal cortex at 10 pulses per second, 120% of motor threshold, for a total of 3000 pulses per day
Number of subjects: 301
Study 18704101 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 301
Study 17311688 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine followed by Docetaxel
Number of subjects: 330
Study 17311688 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel followed by Gemcitabine
Number of subjects: 330
Study 15295352 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (RLX) 60 mg/day
Number of subjects: 487
Study 15295352 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-dose escalation (SDE)
Number of subjects: 487
Study 15295352 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 487
Study 11330366 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional antimicrobial prophylaxis (teicoplanin 400 mg)
Number of subjects: 217
Study 11330366 — intervention group
Group type: COMPARATOR
Intervention: Perioperative antibiotic prophylaxis (teicoplanin 800 mg)
Number of subjects: 217
Study 9509504 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (300 IU/kg, subcutaneously, three times a week for 6‐8 weeks)
Number of subjects: 34
Study 9509504 — intervention group
Group type: COMPARATOR
Intervention: Control (no rHuEPO)
Number of subjects: 34
Study 9509504 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO
Number of subjects: 34
Study 8312032 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphical feedback
Number of subjects: 52
Study 8312032 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabular feedback
Number of subjects: 52
Study 8312032 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphical feedback plus facilitator visit
Number of subjects: 52
Study 8312032 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual audit of risk factors
Number of subjects: 52
Study 8312032 — intervention group
Group type: COMPARATOR
Intervention: All feedback types
Number of subjects: 52
Study 3049484 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard hospital discharge feeding gift pack containing formula
Number of subjects: 60
Study 3049484 — intervention group
Group type: EXPERIMENTAL
Intervention: Specially designed study pack that was free of infant formula
Number of subjects: 60
Study 30813701 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal endoscope combined with supporting laryngoscope surgery
Number of subjects: 94
Study 30813701 — intervention group
Group type: COMPARATOR
Intervention: Simply supporting laryngoscope surgery
Number of subjects: 94
Study 28040281 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention Program (LIP)
Number of subjects: 173
Study 26622463 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% 5-ALA for 1.5 h followed by three 20-min doses of infrared radiation once a week for 3 weeks
Number of subjects: 50
Study 26622463 — intervention group
Group type: COMPARATOR
Intervention: Three 20-min doses of infrared radiation without 5-ALA once a week for 3 weeks
Number of subjects: 50
Study 26622463 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% 5-ALA PDT
Number of subjects: 50
Study 26622463 — intervention group
Group type: COMPARATOR
Intervention: Control group treatment
Number of subjects: 50
Study 23463180 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-assisted parent-administered behavioural intervention (bibliotherapy) with 11 chapter self-help book and 11 weekly telephone consultations
Number of subjects: 48
Study 23463180 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-assisted parent-administered behavioural intervention (bibliotherapy)
Number of subjects: 48
Study 23463180 — intervention group
Group type: COMPARATOR
Intervention: Untreated waitlist control group
Number of subjects: 48
Study 21410369 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 419
Study 21410369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 419
Study 18000162 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (n = 19)
Number of subjects: 45
Study 18000162 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n = 26)
Number of subjects: 45
Study 15882894 — intervention group
Group type: EXPERIMENTAL
Intervention: DX-9065a (1 of 4 weight-adjusted regimens)
Number of subjects: 73
Study 15882894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 14656777 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (ROF) 50 mg
Number of subjects: 20
Study 14656777 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 20
Study 14656777 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 20
Study 12545843 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alpha‐2a 3MIU i.m. once a week for 8 weeks
Number of subjects: 20
Study 12545843 — intervention group
Group type: COMPARATOR
Intervention: Prednisone 1 mg/(kg.d) for 4 weeks
Number of subjects: 20
Study 8873580 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT2) 24 mg daily
Number of subjects: 13
Study 8873580 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril 6 mg daily
Number of subjects: 13
Study 8873580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 1526086 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 12
Study 1526086 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 12
Study 2859256 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (1.2 mg/day)
Number of subjects: 139
Study 2859256 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefarnate (300 mg/day)
Number of subjects: 139
Study 2859256 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of alprazolam and gefarnate
Number of subjects: 139
Study 2859256 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 139
Study 30807279 — intervention group
Group type: EXPERIMENTAL
Intervention: .065 g/dl alcohol dose
Number of subjects: 180
Study 30807279 — intervention group
Group type: COMPARATOR
Intervention: .00 g/dl alcohol dose
Number of subjects: 180
Study 30807279 — intervention group
Group type: COMPARATOR
Intervention: .04 g/dl alcohol dose
Number of subjects: 180
Study 29301367 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO ingestion at 40 g·h‐1
Number of subjects: 20
Study 29301367 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO ingestion at 39 g·h‐1
Number of subjects: 20
Study 29301367 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO ingestion at 20 g·h‐1
Number of subjects: 20
Study 29301367 — intervention group
Group type: COMPARATOR
Intervention: CHO ingestion at 0 g·h‐1 (control - water)
Number of subjects: 20
Study 26924381 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic muscle exercising associated with aerobic exercising
Number of subjects: 40
Study 26924381 — intervention group
Group type: COMPARATOR
Intervention: Only aerobic exercising
Number of subjects: 40
Study 24530167 — intervention group
Group type: EXPERIMENTAL
Intervention: PtCr‐EES (PROMUS Element platinum‐chromium everolimus‐eluting stent)
Number of subjects: 1530
Study 24530167 — intervention group
Group type: COMPARATOR
Intervention: CoCr‐EES (XIENCE V cobalt‐chromium everolimus‐eluting stent)
Number of subjects: 1530
Study 24530167 — intervention group
Group type: EXPERIMENTAL
Intervention: PtCr‐EES
Number of subjects: 1530
Study 24530167 — intervention group
Group type: COMPARATOR
Intervention: CoCr‐EES
Number of subjects: 1530
Study 22387150 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-management intervention for BD
Number of subjects: 0
Study 22387150 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 20536790 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 29
Study 20536790 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin A (CsA)
Number of subjects: 29
Study 17299612 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with interferon‐alpha (IFN‐alpha)‐2b (three million units, daily for eight weeks followed by three million units, three times a week for a further 16 to 40 weeks) and daily ribavirin (1.0 g to 1.2 g according to weight for 24 to 48 weeks)
Number of subjects: 54
Study 17299612 — intervention group
Group type: COMPARATOR
Intervention: Standard IFN‐alpha2b therapy (three million units, three times weekly for 24 to 48 weeks) and daily ribavirin (1.0 g to 1.2 g according to weight for 24 to 48 weeks)
Number of subjects: 54
Study 15292792 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-coated lag and cortical AO/ASIF screws (Group B)
Number of subjects: 120
Study 15292792 — intervention group
Group type: COMPARATOR
Intervention: Standard lag and cortical AO/ASIF screws (Group A)
Number of subjects: 120
Study 11142669 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Oral‐B Plak Control Ultra electric toothbrush
Number of subjects: 26
Study 11142669 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Oral‐B Plak Control 3D electric toothbrush
Number of subjects: 26
Study 11142669 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 26
Study 9426022 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) 0.5 microg/kg body weight per min
Number of subjects: 40
Study 9426022 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg three times daily with NTG
Number of subjects: 40
Study 9426022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9426022 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg three times daily without NTG
Number of subjects: 40
Study 8608428 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturalistic prospective follow-up study over 2 years
Number of subjects: 40
Study 2469711 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha interferons or adenine arabinoside 5'-monophosphate treatment
Number of subjects: 66
Study 2469711 — intervention group
Group type: COMPARATOR
Intervention: No therapy (untreated controls)
Number of subjects: 66
Study 2469711 — intervention group
Group type: COMPARATOR
Intervention: No therapy (non-responders)
Number of subjects: 66
Study 19507 — intervention group
Group type: EXPERIMENTAL
Intervention: Win 20,836 (8-methoxycyclazocine)
Number of subjects: 0
Study 19507 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 0
Study 29985079 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step approach (75-g glucose load, fasting, 1h, and 2h measurements)
Number of subjects: 249
Study 29985079 — intervention group
Group type: COMPARATOR
Intervention: Two-step approach (50-g glucose load followed by 100-g glucose load if necessary)
Number of subjects: 249
Study 30046942 — intervention group
Group type: EXPERIMENTAL
Intervention: Barley kernel bread (BKB)
Number of subjects: 99
Study 30046942 — intervention group
Group type: COMPARATOR
Intervention: White wheat bread (control)
Number of subjects: 99
Study 30046942 — intervention group
Group type: EXPERIMENTAL
Intervention: High Prevotella/Bacteroides (HP)
Number of subjects: 99
Study 30046942 — intervention group
Group type: EXPERIMENTAL
Intervention: High abundance of both (HPB)
Number of subjects: 99
Study 30046942 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Prevotella/Bacteroides (LP)
Number of subjects: 99
Study 28028994 — intervention group
Group type: EXPERIMENTAL
Intervention: Genexol-PM (300 mg/m², once every 3 weeks) + carboplatin (AUC 5)
Number of subjects: 18
Study 28028994 — intervention group
Group type: EXPERIMENTAL
Intervention: Genexol-PM (220 mg/m², once every 3 weeks) + carboplatin (AUC 5)
Number of subjects: 18
Study 28028994 — intervention group
Group type: EXPERIMENTAL
Intervention: Genexol-PM (260 mg/m², once every 3 weeks) + carboplatin (AUC 5)
Number of subjects: 18
Study 26352813 — intervention group
Group type: EXPERIMENTAL
Intervention: Sebelipase alfa (1 mg/kg, intravenously, every other week)
Number of subjects: 66
Study 26352813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 26352813 — intervention group
Group type: EXPERIMENTAL
Intervention: Sebelipase alfa
Number of subjects: 66
Study 26352813 — intervention group
Group type: COMPARATOR
Intervention: Sebelipase alfa and Placebo
Number of subjects: 66
Study 23345000 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral CP-4126 (100-3000 mg/day)
Number of subjects: 26
Study 23345000 — intervention group
Group type: COMPARATOR
Intervention: Oral CP-4126
Number of subjects: 26
Study 21836088 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline diastolic blood pressure (DBP)
Number of subjects: 1281
Study 21836088 — intervention group
Group type: COMPARATOR
Intervention: Increase in DBP >5 mm Hg from baseline to MRI
Number of subjects: 1281
Study 19882058 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5 mg plus 25 ug of fentanyl
Number of subjects: 61
Study 19882058 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 5 mg plus 25 ug of fentanyl
Number of subjects: 61
Study 16758644 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of bone marrow mononuclear cells
Number of subjects: 44
Study 12033348 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead configuration (dual-coil transvenous defibrillation lead)
Number of subjects: 33
Study 12033348 — intervention group
Group type: COMPARATOR
Intervention: Active can configuration (active pectoral electrode)
Number of subjects: 33
Study 10422902 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced antenatal clinic routines including hematinic and malaria prophylaxis, retraining of staff, group and individual counselling, and community health education.
Number of subjects: 1045
Study 10422902 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care without the additional interventions.
Number of subjects: 1045
Study 7587254 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 treatment
Number of subjects: 0